CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.
Lotus Resources (ASX: LOT) jumped 14% to $0.66 as investors responded to improving uranium market sentiment and progress at its Kayelekera and Letlhakane projects. The company continues to ramp up production in Malawi while advancing plans to become a potential 5.5 M lb-per-year uranium producer.
BrainChip develops low-power edge AI chips via its Akida platform. Recent momentum reflects licensing and product roadmap optimism, but weak revenue, losses, and dilution remain risks. Technically, BRN has broken its downtrend and is testing support near 0.16 to 0.17.
Capricorn Metals (ASX: CMM) delivers strong cash generation and mine expansion momentum, positioning for 300koz annual production through Karlawinda and Mt Gibson growth. Premium valuation reflects execution strength and long-life margins.
Red Metal (ASX: RDM) surged toward $0.18 on strong trading volume as investors responded to encouraging rare earth results from the Sybella Project and ongoing exploration success. Growing momentum, expanding activity, and renewed interest have pushed the stock to multi-month highs.
Metallium (ASX: MTM), a pre-revenue metal recovery and exploration company, has lost momentum as commercialisation delays and cash-runway concerns replaced hype. Technically, MTM is testing major support near 0.475, but a confirmed reversal has not yet appeared.
